Hepatitis delta virus and the host response: current status and future perspectives.
The demonstration that recombinant vaccinia can control the level of viraemia after HDV superinfection raises the possibility that established HBV carriers can be immunized against HDV. Furthermore the likelihood that this protective effect is dependent on the induction of a CTL response to HDV raises the possibility that the therapeutic effect of interferon operates by the induction of this cellular response. The failure of interferon to exert a direct inhibitory effect on HDV replication needs further investigation as does the nature of the immune responses involved in the protective effect induced by immunization with recombinant vaccinia.
Department of Medicine, St. Mary's Hospital Medical School, Imperial College of Science, Technology and Medicine, London University, U.K.
H C
HC
Thomas
P
P
Karayiannis
J
J
Monjardino
A
A
McNair
D000818:Animals; D002353:Carrier State / Q000276:immunology; D003588:Cytopathogenic Effect, Viral; D006509:Hepatitis B / Q000150:complications / Q000276:immunology; D003699:Hepatitis D / Q000150:complications / Q000276:immunology* / Q000473:pathology; D003698:Hepatitis Delta Virus / Q000276:immunology*; D006801:Humans; D008099:Liver / Q000276:immunology / Q000473:pathology; D015163:Superinfection / Q000276:immunology